These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 19813328)
41. [Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates]. Cybulska B; Kłosiewicz-Latoszek L Kardiol Pol; 2005 Jun; 62 Suppl 2():II45-50. PubMed ID: 19813336 [No Abstract] [Full Text] [Related]
42. [Influence of ACE inhibitors and fibrates on endothelial function]. Januszewicz A Kardiol Pol; 2005 Jun; 62 Suppl 2():II60-4. PubMed ID: 19813338 [No Abstract] [Full Text] [Related]
43. [The prevention of coronary disease in clinical practice. The recommendations of the Second Joint Task Force of European Societies on the Prevention of Coronary Pathology. Società Europea di Cardiologia, Società Europea dell'Aterosclerosi, Società Europea dell'Ipertensione]. Wood D; De Backer G; Faergeman O; Graham I; Mancia G; Pyörälä K Ital Heart J Suppl; 2000 May; 1(5):692-8. PubMed ID: 10834137 [No Abstract] [Full Text] [Related]
48. [Joint recommendations of Israel medical societies for prevention of coronary heart disease and atherosclerosis]. Harats D; Rubinstein A Harefuah; 2000 Jan; 138(1):66-74. PubMed ID: 10868184 [No Abstract] [Full Text] [Related]
49. Drug therapy for coronary heart disease: the Sheffield table. Ramsay LE; Wallis EJ; Haq IU; Yeo WW; Jackson PR Lancet; 1998 Feb; 351(9100):443-4. PubMed ID: 9482325 [No Abstract] [Full Text] [Related]
50. Torcetrapib: when global risk reduction goes 'off target'. Jackson G Int J Clin Pract; 2008 Feb; 62(2):173-4. PubMed ID: 18199271 [No Abstract] [Full Text] [Related]
52. HDL Cholesterol: Metabolic Pathways and Drug Developments. 4th International Conference, March 2-4, 2003, Cambridge, MA, USA. Scriabine A Cardiovasc Drug Rev; 2003; 21(2):143-50. PubMed ID: 12903649 [No Abstract] [Full Text] [Related]
53. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. Pyörälä K; Wood D Eur Heart J; 1998 Oct; 19(10):1413-5. PubMed ID: 9820979 [No Abstract] [Full Text] [Related]
54. Barriers to the use of statins. Penston J Br J Gen Pract; 2003 Nov; 53(496):886; author reply 887. PubMed ID: 14702911 [No Abstract] [Full Text] [Related]
55. Communicating the risk reduction achieved by cholesterol reducing drugs. Skolbekken JA BMJ; 1998 Jun; 316(7149):1956-8. PubMed ID: 9641937 [No Abstract] [Full Text] [Related]